May 2022

First-Line Regimens for HR+, ERBB2/HER2- Metastatic Breast Cancer
Although a large number of treatment regimens have been studied for hormone receptor-positive (HR+), Erb-B2 receptor tyrosine kinase 2 (ERBB2)/HER2-negative (HER2-) metastatic breast cancer (MBC), there have been few head-to-head trials comparing the efficacy of these regimens. A recent study provides pharmacists with insight into the rank order of first-line treatments of HR+/ERBB2- MBC, which can be used to help optimize patient care. Read more.


BC Disparities With Race, Ethnicity, and Precision Oncology
The BMC Medicine published a forum article gathering breast cancer (BC) specialists from around the world to discuss the impact on race and ethnicity on diagnostic and treatment disparities and the implications of these inequities for precision oncology. The authors discuss structural barriers to health equity in the United States and how this impacts BC. Learn more about this article.

Chronic Disease Incidence in Breast Cancer Survivors
The 5-year survival for breast cancer is around 93%. Women with BC are living longer and are more likely to develop chronic diseases. Much has been written about the increased risk of developing cardiovascular disease, osteopenia, osteoporosis, bone fractures, hypothyroidism, and secondary malignancies, but there is a lack of information on the temporal pattern of the onset of these and other chronic conditions. Read more.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App